GOODWILL AND INTANGIBLE ASSETS (Tables)

3 Months Ended

Jan. 01, 2021

Goodwill and Intangible Assets Disclosure [Abstract]

Goodwill by Reportable Operating Segment

The following table summarizes the activity of goodwill by reportable operating segment: 

(In millions)	Oncology Systems		Other		Total
Balance at October 2, 2020	$	454.7	$	169.2	$	623.9
Measurement period adjustments to business combinations in prior year	0.5		—		0.5
Foreign currency translation adjustments	0.2		3.1		3.3
Balance at January 1, 2021	$	455.4	$	172.3	$	627.7

Indefinite-Lived Intangible Assets

The following table summarizes the gross carrying amount and accumulated amortization of the Company's intangible assets: 

	January 1, 2021						October 2, 2020
(In millions)	Gross Carrying Amount		Accumulated Amortization		Net Carrying Amount		Gross Carrying Amount		Accumulated Amortization		Net Carrying Amount
Technologies and patents	$	229.8	$	(117.1)	$	112.7	$	228.0	$	(110.9)	$	117.1
Customer contracts, supplier relationships, and partner relationships	130.6		(37.6)		93.0		128.9		(34.7)		94.2
Trade names	53.1		(7.8)		45.3		53.0		(7.0)		46.0
Other	7.8		(6.3)		1.5		7.8		(6.1)		1.7
Total intangible with finite lives	421.3		(168.8)		252.5		417.7		(158.7)		259.0
In-process research and development with indefinite lives	12.5		—		12.5		12.3		—		12.3
Total intangible assets	$	433.8	$	(168.8)	$	265.0	$	430.0	$	(158.7)	$	271.3

Finite-Lived Intangible Assets

The following table summarizes the gross carrying amount and accumulated amortization of the Company's intangible assets: 

	January 1, 2021						October 2, 2020
(In millions)	Gross Carrying Amount		Accumulated Amortization		Net Carrying Amount		Gross Carrying Amount		Accumulated Amortization		Net Carrying Amount
Technologies and patents	$	229.8	$	(117.1)	$	112.7	$	228.0	$	(110.9)	$	117.1
Customer contracts, supplier relationships, and partner relationships	130.6		(37.6)		93.0		128.9		(34.7)		94.2
Trade names	53.1		(7.8)		45.3		53.0		(7.0)		46.0
Other	7.8		(6.3)		1.5		7.8		(6.1)		1.7
Total intangible with finite lives	421.3		(168.8)		252.5		417.7		(158.7)		259.0
In-process research and development with indefinite lives	12.5		—		12.5		12.3		—		12.3
Total intangible assets	$	433.8	$	(168.8)	$	265.0	$	430.0	$	(158.7)	$	271.3

Future Amortization Expense

As of January 1, 2021, the Company estimates its remaining amortization expense for intangible assets with finite lives will be as follows (in millions):

Fiscal Years:	Remaining Amortization Expense
Remainder of 2021	$	27.8
2022	36.3
2023	34.9
2024	27.7
2025	22.7
Thereafter	103.1
Total remaining amortization for intangible assets	$	252.5